Clinical Trial Detail

NCT ID NCT02519322
Title Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Ipilimumab

Nivolumab

Age Groups: adult

No variant requirements are available.